ClinicalTrials.gg
CompletedNCT00510718Updated Oct 3, 2019Results posted

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

A Phase 1 interventional study of MDV3100 in Prostate Cancer and Hormone Refractory Prostate Cancer, sponsored by Pfizer. Completed at 9 sites in United States. Open to male participants. Per ClinicalTrials.gov, last updated 2019-10-03.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
33rd of 125
140 · median 52
Started
2007
the only one that year
Phase 1
22 of 125
2 open now
Registered
2nd of 125
by date
Lead sponsor
12 of 125
Pfizer

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 33rd largest by enrollment, is the only one that started in 2007, is one of 22 in phase 1, and was the 2nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response.

Read the detailed description

This is a Phase 1, open-label, uncontrolled, dose-escalation study with dose-expansion at doses determined to be tolerated. Patients who tolerate the drug and do not progress will be allowed to continue treatment. The study endpoints are safety and tolerability and pharmacokinetics. PSA values will also be collected to look for PSA response.

03

Conditions studied

  • Prostate Cancer
  • Hormone Refractory Prostate Cancer

Keywords

  • Prostate
  • Cancer
  • Hormone
  • Refractory
  • Castration
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed adenocarcinoma of the prostate;
  2. Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration);
  3. Progressive disease after medical or surgical castration,

Exclusion criteria

Exclusion Criteria:

  1. in the brain or active epidural disease. (Note: patients with treated epidural disease are allowed);
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    1

    MDV3100

    Drug: MDV3100

Interventions

  • MDV3100 daily until progression or dose-limiting toxicity

    Also known as: enzalutamide, Xtandi

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)

    An adverse events (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both SAEs and non-SAEs.

    Time frame: Baseline up to 30 days after last dose of study treatment (approximately maximum of 129 months)

  2. Percentage of Participants With at Least 1 Dose-limiting Toxicity (DLT): Multiple Dose Period

    DLT was defined as a national cancer institute's common toxicity criteria for adverse events (NCI-CTCAE) version 3.0 grade 3 or greater toxicity regardless of perceived causality that is not improved by the use of adequate/maximal medical intervention. Grade 3 alopecia, fever without neutropenia, nausea, vomiting, fatigue, and self-limited or medically controllable adverse events were not considered as DLTs.

    Time frame: Baseline up to first 35 days of the study treatment in multiple dose period

  3. Maximum Tolerated Dose (MTD) of MDV3100: Multiple Dose Period

    Tolerability was defined as if less than (\<) 4/12 in participants with no prior exposure to MDV3100 (chemo-naive) and \< 4/12 prior chemotherapy participants experienced a DLT within the first 35 days of the multiple dose period. For doses higher than 360 mg/day, tolerability was defined if \<8/24 participants previously treated with chemotherapy experience a DLT within the first 35 days of the multiple dose period. MTD was defined as a dose below the intolerable dose.

    Time frame: Baseline up to first 35 days of the study treatment in multiple dose period

Secondary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Single Dose Period

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24 hours post dose on Day 1 of Single Dose Period

  2. Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of MDV3100: Single Dose Period

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours postdose on Day 1 of Single Dose Period

  3. Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of MDV3100: Single Dose Period

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period

  4. Time to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Single Dose Period

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period

  5. Maximum Plasma Concentration (Cmax) of MDV3100: Single Dose Period

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period

  6. Apparent Terminal Elimination Half-Life (T1/2) of MDV3100: Single Dose Period

    T 1/2 is the time measured for the plasma concentration of MDV3100 to decrease by one half.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period

  7. Apparent Volume of Distribution (V/F) of MDV3100: Single Dose Period

    Volume of distribution is defined as the theoretical volume in which the total amount of MDV3100 would need to be uniformly distributed to produce the desired plasma concentration of MDV3100. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period

  8. Apparent Total Plasma Clearance (CL/F) of MDV3100: Single Dose Period

    Clearance of a MDV3100 is a measure of the rate at which a MDV3100 is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period

  9. Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Multiple Dose Period

    Time frame: Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period

  10. Time to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Multiple Dose Period

    Time frame: Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period

  11. Maximum Plasma Concentration (Cmax) of MDV3100: Multiple Dose Period

    Time frame: Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period

  12. Minimum Observed Plasma Concentration (Cmin) of MDV3100: Multiple Dose Period

    Time frame: Pre-dose on Day 1 of Multiple Dose Period

  13. Apparent Total Plasma Clearance (CL/F) of MDV3100: Multiple Dose Period

    Clearance of a MDV3100 is a measure of the rate at which a MDV3100 is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

    Time frame: Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period

Other outcomes

  1. Percentage of Participants With Prostate Specific Antigen (PSA) Response at Day 84: Multiple Dose Period

    Prostate-specific antigen is a glycoprotein considered as a biomarker for the response to therapy in men with prostate cancer. A 50 percent (%) decline in PSA from baseline to the PSA level at Day 84 was considered as a PSA response.

    Time frame: Baseline, Day 84

07

Results

Posted Oct 3, 2019

Participant flow

Single Dose Period: 1 Week
Participant flow — Single Dose Period: 1 Week
MilestoneMDV3100 (Enzalutamide): No Previous ChemotherapyMDV3100 (Enzalutamide): Post Chemotherapy
Started1512
30 mg/day30
60 mg/day30
150/160 mg/day21
240 mg/day30
360 mg/day42
480 mg/day06
600 mg/day03
Completed1512
Not completed00
Multiple Dose Period: 12 Weeks
Participant flow — Multiple Dose Period: 12 Weeks
MilestoneMDV3100 (Enzalutamide): No Previous ChemotherapyMDV3100 (Enzalutamide): Post Chemotherapy
Started6575
30 mg/day30
60 mg/day1512
150/160 mg/day1513
240 mg/day1712
360 mg/day1513
480 mg/day022
600 mg/day03
Completed5043
Not completed1532
Withdrew: Adverse event18
Withdrew: Psa disease progression36
Withdrew: Radiologic disease progression811
Withdrew: Clinical disease progression13
Withdrew: Withdrawal by subject13
Withdrew: Other11

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)

An adverse events (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both SAEs and non-SAEs.

Time frame:
Baseline up to 30 days after last dose of study treatment (approximately maximum of 129 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)
ParticipantsMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /DayMDV3100 (Enzalutamide) 160 mg /Day: Long Term Dosing Period
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)0614861110
PrimaryPercentage of Participants With at Least 1 Dose-limiting Toxicity (DLT): Multiple Dose Period

DLT was defined as a national cancer institute's common toxicity criteria for adverse events (NCI-CTCAE) version 3.0 grade 3 or greater toxicity regardless of perceived causality that is not improved by the use of adequate/maximal medical intervention. Grade 3 alopecia, fever without neutropenia, nausea, vomiting, fatigue, and self-limited or medically controllable adverse events were not considered as DLTs.

Time frame:
Baseline up to first 35 days of the study treatment in multiple dose period
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Dose-limiting Toxicity (DLT): Multiple Dose Period
percentage of participantsMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Percentage of Participants With at Least 1 Dose-limiting Toxicity (DLT): Multiple Dose Period0000112
PrimaryMaximum Tolerated Dose (MTD) of MDV3100: Multiple Dose Period

Tolerability was defined as if less than (\<) 4/12 in participants with no prior exposure to MDV3100 (chemo-naive) and \< 4/12 prior chemotherapy participants experienced a DLT within the first 35 days of the multiple dose period. For doses higher than 360 mg/day, tolerability was defined if \<8/24 participants previously treated with chemotherapy experience a DLT within the first 35 days of the multiple dose period. MTD was defined as a dose below the intolerable dose.

Time frame:
Baseline up to first 35 days of the study treatment in multiple dose period
Reported as:
Number · milligrams per day
Maximum Tolerated Dose (MTD) of MDV3100: Multiple Dose Period
milligrams per dayMDV3100 (Enzalutamide) : All Participants
Maximum Tolerated Dose (MTD) of MDV3100: Multiple Dose Period240
SecondaryArea Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Single Dose Period
Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 24 hours post dose on Day 1 of Single Dose Period
Reported as:
Geometric mean · microgram*hour per milliliter
Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Single Dose Period
microgram*hour per milliliterMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Single Dose Period5.43 ± 11.8015.64 ± 3.5038.21 ± 23.6458.39 ± 47.6479.26 ± 19.29——
SecondaryArea Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of MDV3100: Single Dose Period
Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours postdose on Day 1 of Single Dose Period
Reported as:
Geometric mean · microgram*hour per milliliter
Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of MDV3100: Single Dose Period
microgram*hour per milliliterMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of MDV3100: Single Dose Period21.2 ± 14.253.1 ± 4.1145.3 ± 10.0208.5 ± 44.0320.2 ± 12.9363.4 ± 38.7391.9 ± 14.0
SecondaryArea Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of MDV3100: Single Dose Period
Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Reported as:
Geometric mean · microgram*hour per milliliter
Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of MDV3100: Single Dose Period
microgram*hour per milliliterMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of MDV3100: Single Dose Period51.3 ± 39.892.7 ± 19.0331.5 ± 14.6459.2 ± 32.7706.7 ± 17.7952.7 ± 42.4865.0 ± 34.6
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Single Dose Period
Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Single Dose Period
hoursMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Time to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Single Dose Period1.98 (0.42 to 4.00)0.50 (0.48 to 1.00)0.53 (0.50 to 1.98)1.00 (0.57 to 1.00)1.03 (0.53 to 2.20)1.54 (0.53 to 2.08)1.03 (1.03 to 2.00)
SecondaryMaximum Plasma Concentration (Cmax) of MDV3100: Single Dose Period
Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Reported as:
Geometric mean · microgram per milliliter
Maximum Plasma Concentration (Cmax) of MDV3100: Single Dose Period
microgram per milliliterMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Maximum Plasma Concentration (Cmax) of MDV3100: Single Dose Period0.43 ± 15.971.65 ± 28.773.30 ± 22.855.19 ± 18.646.68 ± 39.615.93 ± 66.035.17 ± 19.51
SecondaryApparent Terminal Elimination Half-Life (T1/2) of MDV3100: Single Dose Period

T 1/2 is the time measured for the plasma concentration of MDV3100 to decrease by one half.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Reported as:
Mean · hours
Apparent Terminal Elimination Half-Life (T1/2) of MDV3100: Single Dose Period
hoursMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Apparent Terminal Elimination Half-Life (T1/2) of MDV3100: Single Dose Period164.9 ± 69.8100.5 ± 30.9143.7 ± 34.8138.9 ± 22.6149.1 ± 26.1144.0 ± 68.4130.4 ± 37.7
SecondaryApparent Volume of Distribution (V/F) of MDV3100: Single Dose Period

Volume of distribution is defined as the theoretical volume in which the total amount of MDV3100 would need to be uniformly distributed to produce the desired plasma concentration of MDV3100. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Reported as:
Geometric mean · liters
Apparent Volume of Distribution (V/F) of MDV3100: Single Dose Period
litersMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Apparent Volume of Distribution (V/F) of MDV3100: Single Dose Period131.7 ± 15.690.5 ± 16.091.89 ± 13.31103.8 ± 48.5108.2 ± 15.897.4 ± 30.7126.4 ± 8.8
SecondaryApparent Total Plasma Clearance (CL/F) of MDV3100: Single Dose Period

Clearance of a MDV3100 is a measure of the rate at which a MDV3100 is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Reported as:
Geometric mean · liters per hour
Apparent Total Plasma Clearance (CL/F) of MDV3100: Single Dose Period
liters per hourMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Apparent Total Plasma Clearance (CL/F) of MDV3100: Single Dose Period0.585 ± 39.8100.647 ± 18.9880.453 ± 14.5830.523 ± 32.6790.509 ± 17.7110.504 ± 42.4370.694 ± 34.625
SecondaryArea Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Multiple Dose Period
Time frame:
Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period
Reported as:
Geometric mean · microgram*hour per milliliter
Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Multiple Dose Period
microgram*hour per milliliterMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Multiple Dose Period60.0 ± 21.0109.8 ± 34.4291.7 ± 24.9395.7 ± 27.4488.9 ± 23.9463.1 ± NA—
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Multiple Dose Period
Time frame:
Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Multiple Dose Period
hoursMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Time to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Multiple Dose Period2.07 (1.00 to 3.92)1.07 (0.50 to 23.67)1.00 (0.00 to 25.80)1.08 (0.00 to 26.17)1.57 (0.48 to 24.08)0.00 (0.00 to 0.00)—
SecondaryMaximum Plasma Concentration (Cmax) of MDV3100: Multiple Dose Period
Time frame:
Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period
Reported as:
Geometric mean · microgram per milliliter
Maximum Plasma Concentration (Cmax) of MDV3100: Multiple Dose Period
microgram per milliliterMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Maximum Plasma Concentration (Cmax) of MDV3100: Multiple Dose Period2.76 ± 21.105.49 ± 28.8814.07 ± 25.3618.91 ± 26.5724.57 ± 21.0027.90 ± NA—
SecondaryMinimum Observed Plasma Concentration (Cmin) of MDV3100: Multiple Dose Period
Time frame:
Pre-dose on Day 1 of Multiple Dose Period
Reported as:
Mean · microgram per milliliter
Minimum Observed Plasma Concentration (Cmin) of MDV3100: Multiple Dose Period
microgram per milliliterMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Minimum Observed Plasma Concentration (Cmin) of MDV3100: Multiple Dose Period0.10 ± 0.030.00 ± 0.000.04 ± 0.190.00 ± 0.000.00 ± 0.000.00 ± 0.001.89 ± 0.55
SecondaryApparent Total Plasma Clearance (CL/F) of MDV3100: Multiple Dose Period

Clearance of a MDV3100 is a measure of the rate at which a MDV3100 is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

Time frame:
Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period
Reported as:
Mean · liters per hour
Apparent Total Plasma Clearance (CL/F) of MDV3100: Multiple Dose Period
liters per hourMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Apparent Total Plasma Clearance (CL/F) of MDV3100: Multiple Dose Period0.507 ± 0.1110.580 ± 0.2450.530 ± 0.1490.628 ± 0.1790.755 ± 0.1761.037 ± NA—
Other pre-specifiedPercentage of Participants With Prostate Specific Antigen (PSA) Response at Day 84: Multiple Dose Period

Prostate-specific antigen is a glycoprotein considered as a biomarker for the response to therapy in men with prostate cancer. A 50 percent (%) decline in PSA from baseline to the PSA level at Day 84 was considered as a PSA response.

Time frame:
Baseline, Day 84
Reported as:
Number · percentage of participants
Percentage of Participants With Prostate Specific Antigen (PSA) Response at Day 84: Multiple Dose Period
percentage of participantsMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /Day
Percentage of Participants With Prostate Specific Antigen (PSA) Response at Day 84: Multiple Dose Period33.3 (0.8 to 90.6)50.0 (29.1 to 70.9)66.7 (44.7 to 84.4)75.0 (50.9 to 91.3)71.4 (47.8 to 88.7)45.5 (16.7 to 76.6)—

Adverse events

Collected over Baseline up to 30 days after last dose of study treatment (approximately maximum of 129 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MDV3100 (Enzalutamide) 30 mg/Day—0/3 (0%)3/3 (100%)
MDV3100 (Enzalutamide) 60 mg /Day—6/27 (22.2%)27/27 (100%)
MDV3100 (Enzalutamide) 150/160 mg/Day—14/28 (50%)27/28 (96.4%)
MDV3100 (Enzalutamide) 240 mg /Day—8/29 (27.6%)29/29 (100%)
MDV3100 (Enzalutamide) 360 mg /Day—6/28 (21.4%)28/28 (100%)
MDV3100 (Enzalutamide) 480 mg /Day—1/22 (4.5%)21/22 (95.5%)
MDV3100 (Enzalutamide) 600 mg /Day—1/3 (33.3%)3/3 (100%)
MDV3100 (Enzalutamide) 160 mg /Day: Long Term Dosing Period—10/18 (55.6%)17/18 (94.4%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /DayMDV3100 (Enzalutamide) 160 mg /Day: Long Term Dosing Period
ConvulsionNervous system disorders0/30/270/280/291/281/221/30/18
Confusional statePsychiatric disorders0/30/270/280/290/280/221/30/18
Myocardial infarctionCardiac disorders0/30/270/280/291/280/220/32/18
PneumoniaInfections and infestations0/30/271/280/290/280/220/32/18
Spinal cord compressionNervous system disorders0/30/270/281/291/280/220/32/18
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/31/270/280/290/280/220/32/18
Acute myocardial infarctionCardiac disorders0/30/270/280/290/280/220/32/18
ArthralgiaMusculoskeletal and connective tissue disorders0/32/270/280/290/280/220/30/18
AnaemiaBlood and lymphatic system disorders0/30/270/280/292/280/220/30/18
FatigueGeneral disorders0/30/270/282/292/280/220/30/18
Most frequent other events
Showing 10 of 405
Most frequent other events
EventMDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /DayMDV3100 (Enzalutamide) 160 mg /Day: Long Term Dosing Period
FatigueGeneral disorders2/317/2719/2820/2923/2816/221/313/18
NauseaGastrointestinal disorders1/36/2711/286/2919/2811/222/30/18
ConstipationGastrointestinal disorders2/310/278/287/2911/286/221/36/18
DiarrhoeaGastrointestinal disorders2/37/278/283/294/289/221/38/18
VomitingGastrointestinal disorders0/35/273/281/296/284/222/31/18
Back painMusculoskeletal and connective tissue disorders2/311/275/288/299/286/221/35/18
DizzinessNervous system disorders2/34/277/285/297/284/220/31/18
Sinus headacheNervous system disorders2/30/270/280/290/280/220/30/18
FlatulenceGastrointestinal disorders2/31/272/282/292/280/220/30/18
ArthralgiaMusculoskeletal and connective tissue disorders1/311/278/287/298/285/220/38/18

Baseline characteristics

Safety population included all enrolled participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)MDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /DayTotal
<=18 years00000000
Between 18 and 65 years115108107354
>=65 years21218211815086
Sex: Female, Male
Sex: Female, Male(Participants)MDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /DayTotal
Female00000000
Male327282928223140
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /DayTotal
Hispanic or Latino03011005
Not Hispanic or Latino324282727223134
Unknown or Not Reported00010001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MDV3100 (Enzalutamide) 30 mg/DayMDV3100 (Enzalutamide) 60 mg /DayMDV3100 (Enzalutamide) 150/160 mg/DayMDV3100 (Enzalutamide) 240 mg /DayMDV3100 (Enzalutamide) 360 mg /DayMDV3100 (Enzalutamide) 480 mg /DayMDV3100 (Enzalutamide) 600 mg /DayTotal
American Indian or Alaska Native00001001
Asian00000000
Native Hawaiian or Other Pacific Islander00000000
Black or African American01012004
White326282825223135
More than one race00000000
Unknown or Not Reported00000000
08

Study locations

9 sites
  • Dana-Farber Cancer Institute (DFCI)
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center (BIDMC)
    Boston, Massachusetts 02215, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • MSKCC- Sidney Kimmel Center
    New York, New York 10065, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Investigational Pharmacy Services
    Houston, Texas 77030-4009, United States
  • The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
09

References and documents

Publications

  • Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt JS, Beddo V, de Vries M, Mordenti J. Clinical Pharmacokinetic Studies of Enzalutamide. Clin Pharmacokinet. 2015 Oct;54(10):1043-55. doi: 10.1007/s40262-015-0271-5. PubMed 25917876 ↗
  • Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14. PubMed 20398925 ↗

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2007 to primary completion in Dec 2008, 16 months.

Results were first posted in Oct 2019, 10 years 9 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 16 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2007
First posted
Aug 2, 2007
StartActual
Jul 23, 2007
Primary completionActual
Dec 8, 2008
CompletionActual
Apr 2, 2018
Results first posted
Oct 3, 2019
Last update
Oct 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00510718
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Aug 2, 2007
Start date
Jul 23, 2007
Primary completion
Dec 8, 2008
Completion
Apr 2, 2018
Results posted
Oct 3, 2019
Last update
Oct 3, 2019

Study contacts

Pfizer Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion